Zur Kurzanzeige

dc.contributor.authorZazo Gómez, Hinojal 
dc.contributor.authorColino Gandarillas, Clara Isabel 
dc.contributor.authorGutiérrez Millán, María Carmen 
dc.contributor.authorCordero, Andres A
dc.contributor.authorBartneck, Matthias
dc.contributor.authorLanao, José M 
dc.date.accessioned2025-01-15T15:40:56Z
dc.date.available2025-01-15T15:40:56Z
dc.date.issued2022-02-13
dc.identifier.citationZazo H, Colino CI, Gutiérrez-Millán C, Cordero AA, Bartneck M, Lanao JM. Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution. Pharmaceutics. 2022 Feb 13;14(2):406. doi: 10.3390/pharmaceutics14020406. PMID: 35214138; PMCID: PMC8875329.es_ES
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10366/161816
dc.description.abstractComputational modelling has gained attention for evaluating nanoparticle-based drug delivery systems. Physiologically based pharmacokinetic (PBPK) modelling provides a mechanistic approach for evaluating drug biodistribution. The aim of this work is to develop a specific PBPK model to simulate stavudine biodistribution after the administration of a 40 nm gold nanoparticle-based drug delivery system in rats. The model parameters used have been obtained from literature, in vitro and in vivo studies, and computer optimization. Based on these, the PBPK model was built, and the compartments included were considered as permeability rate-limited tissues. In comparison with stavudine solution, a higher biodistribution of stavudine into HIV reservoirs and the modification of pharmacokinetic parameters such as the mean residence time (MRT) have been observed. These changes are particularly noteworthy in the liver, which presents a higher partition coefficient (from 0.27 to 0.55) and higher MRT (from 1.28 to 5.67 h). Simulated stavudine concentrations successfully describe these changes in the in vivo study results. The average fold error of predicted concentrations after the administration of stavudine-gold nanoparticles was within the 0.5-2-fold error in all of the tissues. Thus, this PBPK model approach may help with the pre-clinical extrapolation to other administration routes or the species of stavudine gold nanoparticles.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPBPK modeles_ES
dc.subjectBiodistribution
dc.subjectGold nanoparticles
dc.subjectPharmacokinetics
dc.subjectStavudine
dc.titlePhysiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistributiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/pharmaceutics14020406
dc.identifier.doi10.3390/pharmaceutics14020406
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid35214138
dc.journal.titlePharmaceuticses_ES
dc.volume.number14es_ES
dc.issue.number2es_ES
dc.page.initial406es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional